Suppr超能文献

相似文献

1
Polyglutamine neurodegeneration: protein misfolding revisited.
Trends Neurosci. 2008 Oct;31(10):521-8. doi: 10.1016/j.tins.2008.07.004. Epub 2008 Sep 6.
2
Differential contributions of Caenorhabditis elegans histone deacetylases to huntingtin polyglutamine toxicity.
J Neurosci. 2006 Mar 8;26(10):2830-8. doi: 10.1523/JNEUROSCI.3344-05.2006.
3
Targeting protein aggregation in neurodegeneration--lessons from polyglutamine disorders.
Expert Opin Ther Targets. 2006 Aug;10(4):505-13. doi: 10.1517/14728222.10.4.505.
4
Novel polyglutamine model uncouples proteotoxicity from aging.
PLoS One. 2014 May 9;9(5):e96835. doi: 10.1371/journal.pone.0096835. eCollection 2014.
5
Yeast as a platform to explore polyglutamine toxicity and aggregation.
Methods Mol Biol. 2013;1017:153-61. doi: 10.1007/978-1-62703-438-8_11.
8
Glutamine repeats: structural hypotheses and neurodegeneration.
Biochem Soc Trans. 2002 Aug;30(4):548-51. doi: 10.1042/bst0300548.
9
Polyglutamine expansion in ataxin-3 does not affect protein stability: implications for misfolding and disease.
J Biol Chem. 2004 Nov 12;279(46):47643-51. doi: 10.1074/jbc.M405799200. Epub 2004 Sep 1.
10
Polyglutamine misfolding in yeast: toxic and protective aggregation.
Prion. 2011 Oct-Dec;5(4):285-90. doi: 10.4161/pri.18071. Epub 2011 Oct 1.

引用本文的文献

2
Loss of FIC-1-mediated AMPylation activates the UPRER and upregulates cytosolic HSP70 chaperones to suppress polyglutamine toxicity.
PLoS Genet. 2025 Jun 13;21(6):e1011723. doi: 10.1371/journal.pgen.1011723. eCollection 2025 Jun.
3
Insights into dentatorubral-pallidoluysian atrophy from a new Drosophila model of disease.
Neurobiol Dis. 2025 Apr;207:106834. doi: 10.1016/j.nbd.2025.106834. Epub 2025 Feb 5.
4
Chaperones as Potential Pharmacological Targets for Treating Protein Aggregation Illness.
Curr Protein Pept Sci. 2025 Jan 27. doi: 10.2174/0113892037338028241230092414.
5
L-arginine in patients with spinocerebellar ataxia type 6: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
EClinicalMedicine. 2024 Nov 25;78:102952. doi: 10.1016/j.eclinm.2024.102952. eCollection 2024 Dec.
7
Why Is Arginine the Only Amino Acid That Inhibits Polyglutamine Monomers from Taking on Toxic Conformations?
ACS Chem Neurosci. 2024 Aug 7;15(15):2925-2935. doi: 10.1021/acschemneuro.4c00276. Epub 2024 Jul 15.
8
Therapeutic Implications and Regulations of Protein Post-translational Modifications in Parkinsons Disease.
Cell Mol Neurobiol. 2024 Jul 3;44(1):53. doi: 10.1007/s10571-024-01471-8.
9
Altered Metabolic Signaling and Potential Therapies in Polyglutamine Diseases.
Metabolites. 2024 May 31;14(6):320. doi: 10.3390/metabo14060320.

本文引用的文献

1
RNA toxicity is a component of ataxin-3 degeneration in Drosophila.
Nature. 2008 Jun 19;453(7198):1107-11. doi: 10.1038/nature06909. Epub 2008 Apr 30.
2
Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: implications for the therapeutic development of RNAi.
Proc Natl Acad Sci U S A. 2008 Apr 15;105(15):5868-73. doi: 10.1073/pnas.0801775105. Epub 2008 Apr 8.
3
Opposing effects of polyglutamine expansion on native protein complexes contribute to SCA1.
Nature. 2008 Apr 10;452(7188):713-8. doi: 10.1038/nature06731. Epub 2008 Mar 12.
4
Adapting proteostasis for disease intervention.
Science. 2008 Feb 15;319(5865):916-9. doi: 10.1126/science.1141448.
6
9
Genome-wide screen for modifiers of ataxin-3 neurodegeneration in Drosophila.
PLoS Genet. 2007 Oct;3(10):1950-64. doi: 10.1371/journal.pgen.0030177.
10
Soluble polyglutamine oligomers formed prior to inclusion body formation are cytotoxic.
Hum Mol Genet. 2008 Feb 1;17(3):345-56. doi: 10.1093/hmg/ddm311. Epub 2007 Oct 18.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验